Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

3,894 total articles

CoreWeave Shares Slip After CEO Disposes of Stake

CoreWeave Shares Slip After CEO Disposes of Stake

CoreWeave Inc. (NYSE: CRWV) shares fell 3.3% after regulatory filings showed CEO Michael Intrator sold more than 80,000 Class A shares on Feb. 11, 2026, following a conversion of Class B stock to Class A. Intrator retains substantial direct and beneficial ownership in the company as it pursues growth in the AI infrastructure market.

DA Davidson Lowers Rivian Rating, Flags Execution Risks for R2 Launch

DA Davidson Lowers Rivian Rating, Flags Execution Risks for R2 Launch

DA Davidson downgraded Rivian to underperform and trimmed its price target to $14 from $15, citing concerns that the company must achieve an unusually strong R2 debut without federal tax-credit support or broad dealer distribution. The firm acknowledged positive early impressions of the R2 and the R1's solid product attributes, but warned that sale…

Insider Filings Show a Quiet Monday Without Notable Trades

Insider Filings Show a Quiet Monday Without Notable Trades

Insider transaction reports filed on Monday, February 16, 2026 contained no material purchases or disposals by company executives or directors. The absence of notable trades leaves little immediate directional signal for investors relying on insider activity as a gauge of management conviction or valuation views.

Rothschild Flags 'Agentic Commerce' as Potential Game Changer for Retailers; Revises Ratings

Rothschild Flags 'Agentic Commerce' as Potential Game Changer for Retailers; Revises Ratings

Rothschild & Co analysts warned that the emergence of agentic commerce - automated systems that handle shopping and replenishment on behalf of consumers - could reconfigure the retail landscape in a manner comparable to the early rise of ecommerce. The bank left Walmart on Buy, upgraded Dollar Tree to Buy, downgraded Dollar General to Sell and kept…

IPO Plans Falter in 2026 as Volatile Markets and Valuation Pressure Bite

IPO Plans Falter in 2026 as Volatile Markets and Valuation Pressure Bite

A wave of postponements and reduced deal sizes has hit 2026 initial public offerings in the United States as market turbulence, tougher valuation checks and weak peer showings curb the pipeline for new listings. Notable issuers including Clear Street, Agibank and Liftoff Mobile have each taken steps to trim or halt plans while monitoring conditions…

Warner Bros Discovery Turns Down Paramount Skydance’s Latest $30 Offer, Invites Improved Bid

Warner Bros Discovery Turns Down Paramount Skydance’s Latest $30 Offer, Invites Improved Bid

Warner Bros Discovery has declined Paramount Skydance’s revised hostile takeover offer of $30 per share, while allowing the suitor a seven-day window to present a higher proposal. Paramount purportedly floated an informal $31-per-share price that prompted the company to set a deadline of February 23 for a "best and final" bid. Under the terms of Wa…

eToro Posts Q4 Gains, Surpasses Profit Estimates on Multi-Asset Demand

eToro Posts Q4 Gains, Surpasses Profit Estimates on Multi-Asset Demand

eToro reported fourth-quarter adjusted earnings that exceeded analyst expectations, supported by growth across the range of asset classes it offers. The company saw its assets under administration rise year-on-year even as net contribution from crypto and margin-related items declined. Broader market dynamics during the quarter included rising U.S.…

Ocular Therapeutix Shares Slide After SOL-1 Top-Line Results for Axpaxli, Despite Statistically Significant Outcomes

Ocular Therapeutix Shares Slide After SOL-1 Top-Line Results for Axpaxli, Despite Statistically Significant Outcomes

Ocular Therapeutix (OCUL) saw its stock fall 25% after releasing top-line results from the Phase 3 SOL-1 superiority trial of Axpaxli in wet age-related macular degeneration (AMD). The study reached its primary endpoint, with Axpaxli outperforming Regeneron’s Eylea on the percentage of patients maintaining visual acuity at both 36 and 52 weeks. Mar…